These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 24950434

  • 1. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K, Persson U.
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ, Chubb BD, Smith IC, Valentine WJ.
    Diabet Med; 2012 Mar; 29(3):313-20. PubMed ID: 21883438
    [Abstract] [Full Text] [Related]

  • 4. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC, Samyshkin Y, Langer J, Palmer JL.
    J Med Econ; 2012 Mar; 15 Suppl 2():28-37. PubMed ID: 22834986
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R.
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [Abstract] [Full Text] [Related]

  • 6. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC, Conner C, Hammer M.
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [Abstract] [Full Text] [Related]

  • 8. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J, Hunt B, Valentine WJ.
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
    Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N.
    BMC Health Serv Res; 2014 Sep 22; 14():419. PubMed ID: 25245666
    [Abstract] [Full Text] [Related]

  • 10. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov 22; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S, Deng J, Shi L, Mu Y, Dong H.
    J Med Econ; 2015 Nov 22; 18(10):808-20. PubMed ID: 25950193
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC, Conner C, Hammer M.
    Curr Med Res Opin; 2011 May 22; 27(5):897-906. PubMed ID: 21348806
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å, Pollock RF, Hunt B, Valentine WJ.
    J Med Econ; 2013 Dec 22; 16(12):1442-52. PubMed ID: 24147661
    [Abstract] [Full Text] [Related]

  • 14. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.
    J Med Econ; 2012 Dec 22; 15 Suppl 2():1-5. PubMed ID: 22853443
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
    Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Hunt B, Valentine WJ.
    J Med Econ; 2016 Dec 22; 19(2):121-34. PubMed ID: 26413789
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM, Schultz NM, Lee TA.
    Pharmacoeconomics; 2014 Nov 22; 32(11):1079-91. PubMed ID: 25052903
    [Abstract] [Full Text] [Related]

  • 17. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R.
    Clin Ther; 2017 Jul 22; 39(7):1347-1359. PubMed ID: 28625506
    [Abstract] [Full Text] [Related]

  • 18. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS.
    Diabetes Obes Metab; 2018 Aug 22; 20(8):1921-1927. PubMed ID: 29652101
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, Valentine WJ, Palmer AJ.
    Value Health; 2008 Mar 22; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R.
    BMC Health Serv Res; 2018 Feb 01; 18(1):78. PubMed ID: 29391064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.